Align Technology Appoints Paul J. Clancy and Ian Bell to Its Board of Directors

Align Technology Appoints Paul J. Clancy and Ian Bell to Board of Directors, Strengthening Healthcare and Operational Leadership

Align Technology, a global medical device company specializing in digital orthodontics and restorative dentistry, has announced the appointment of two experienced healthcare industry executives, Paul J. Clancy and Ian Bell, to its Board of Directors. The appointments are intended to strengthen the Board’s financial, strategic, commercial and operational expertise as the company continues to pursue its long-term business objectives and growth strategy.

Mr. Clancy, a biopharmaceutical industry executive and former Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc. and Biogen Inc., has joined Align’s Board effective immediately. Mr. Bell, who currently serves as Senior Vice President and Chief Operating Officer of Alcon Inc., will join the Board effective December 10, 2026.

Both executives bring substantial experience in the global healthcare sector, including leadership roles involving financial management, business strategy, product innovation, manufacturing, quality, regulatory operations and international commercial activities. Their backgrounds are expected to complement the existing capabilities of Align’s Board and support the company’s continued development across its medical technology businesses.

Align Technology designs, manufactures and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and exocad™ computer-aided design and manufacturing (CAD/CAM) software. Its technologies support digital orthodontics and restorative dentistry by providing tools for dental professionals to plan and deliver treatment, capture digital impressions and develop restorative dental solutions.

The appointments come as Align continues to operate across a global dental technology market that increasingly relies on digital workflows, advanced imaging, software integration and innovative treatment approaches. The addition of executives with experience in biotechnology, pharmaceuticals, ophthalmic medical devices and global healthcare operations is expected to provide further perspectives as the company evaluates business opportunities and executes its strategic priorities.

Align Leadership Highlights Strategic and Operational Expertise

Kevin Conroy, Chairman of the Board of Align Technology, welcomed both appointments and emphasized the value of their experience across different areas of the healthcare industry.

“We are pleased to welcome Paul Clancy to our Board and look forward to the addition of Ian Bell in December,” Conroy said. “Paul and Ian bring significant global healthcare, financial, innovation and operational leadership experience that will complement the strengths of Align’s Board.”

He also highlighted the specific contributions each executive is expected to bring to the company. According to Conroy, Clancy’s financial and strategic leadership experience in the biopharmaceutical industry will complement Bell’s background in commercial operations, manufacturing, quality and regulatory management.

“Paul’s deep financial and strategic leadership in the biopharmaceutical industry, together with Ian’s broad perspective across commercial, manufacturing, quality and regulatory operations and his experience leading innovation-driven businesses, will be valuable as we continue to execute our strategy and drive long-term growth,” Conroy added.

The appointments reflect Align’s intention to bring a broad range of industry perspectives into its Board-level discussions. Clancy’s experience managing financial strategy at major pharmaceutical companies and Bell’s leadership across international medical device operations provide different but complementary areas of expertise.

Paul J. Clancy Brings More Than 30 Years of Financial and Strategic Leadership

Paul J. Clancy joins Align’s Board with more than 30 years of strategic, financial and operational leadership experience, primarily in the biotechnology and pharmaceutical industries. His career includes senior executive positions at major life sciences companies, as well as board responsibilities at publicly traded and privately held organizations.

One of his most prominent leadership positions was Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, where he served from July 2017 through October 2019. In that role, he was responsible for the company’s financial leadership during a period in which Alexion operated as a major biopharmaceutical business focused on therapies for rare and serious diseases.

Following his departure from the CFO position, Clancy continued to serve as a Senior Advisor to Alexion until July 2020. His experience at the company added to his background in financial strategy, corporate leadership and the management of complex pharmaceutical businesses.

Before joining Alexion, Clancy spent a decade as Executive Vice President and Chief Financial Officer of Biogen, serving from 2007 to 2017. During this period, he led the company’s financial strategy through a decade of growth and held responsibility for important financial and business planning activities.

Clancy originally joined Biogen in 2001 as Vice President of U.S. Marketing. His career at the company subsequently expanded through several senior leadership positions, including Vice President of Portfolio Management and Senior Vice President of Finance.

In these roles, he gained experience across multiple areas of corporate management. His responsibilities included treasury, tax, investor relations and business planning, providing him with a broad understanding of the financial and strategic requirements of a global biopharmaceutical organization.

His experience at Biogen also extended beyond traditional finance functions. His earlier marketing and portfolio management responsibilities gave him exposure to commercial strategy and product portfolio decisions, providing a combination of financial and business leadership experience.

Before joining Biogen, Clancy spent 13 years at PepsiCo, where he held a range of finance, strategy and general management positions. His work at the company provided experience in large-scale corporate operations and business management outside the pharmaceutical sector.

This combination of consumer business, biotechnology and pharmaceutical experience gives Clancy a broad perspective on financial planning, corporate strategy and organizational performance.

Board and Academic Experience Strengthen Clancy’s Profile

In addition to his executive leadership background, Clancy has experience serving on the boards of several healthcare and life sciences companies.

He currently serves on the Board of Directors of Incyte Corporation, where he chairs the Audit and Finance Committee. The role involves oversight responsibilities related to financial reporting, corporate finance and governance.

He also serves as Chair of the Board of Sionna Therapeutics, Inc., adding further board-level leadership experience within the biotechnology sector.

Previously, Clancy served on the boards of Exact Sciences, Xilio Therapeutics and Agios Pharmaceuticals, Inc. These positions provided additional exposure to companies operating across different areas of healthcare research, diagnostics and drug development.

His board experience is complemented by his involvement in business education. Clancy currently serves as an Executive Fellow at Harvard Business School, where his professional experience contributes to discussions and learning related to business leadership and management.

He also served as a Visiting Senior Lecturer of Finance at Cornell University’s Graduate School of Management from 2021 through May 2026. His academic work during this period focused on bringing practical financial leadership experience into an educational environment.

Clancy holds a Bachelor of Science in Business Administration, with a concentration in Finance, from Babson College. He also earned a Master of Business Administration degree from Columbia University.

His background in corporate finance, business strategy, executive management, governance and education is expected to contribute to Align’s Board as it oversees the company’s financial priorities and long-term strategic direction.

Ian Bell Adds Global Medical Technology and Operational Experience

Ian Bell will join Align’s Board effective December 10, 2026, bringing extensive experience in global healthcare and medical technology operations.

Bell currently serves as Senior Vice President and Chief Operating Officer of Alcon Inc., a global eye care company. In his current position, he oversees the company’s commercial, manufacturing, quality and regulatory operations.

His responsibilities cover several important areas of a medical technology business, including the activities required to develop, manufacture and deliver products to healthcare professionals and customers across international markets.

Before assuming the COO role in 2024, Bell served as President, Global Business & Innovation at Alcon. In that position, he led product development across the company’s surgical, vision care and digital health businesses.

The role provided experience across multiple areas of ophthalmic healthcare and medical technology innovation. His responsibilities involved overseeing business and product development activities across different segments, each with distinct customer needs, product requirements and market opportunities.

Bell previously served as President, International and President of Alcon’s Europe, Middle East and Africa region. These positions gave him substantial experience in international business management, regional commercial operations and the challenges associated with serving healthcare markets across different geographies.

His work at Alcon has therefore covered both global product development and regional business leadership, as well as the operational responsibilities associated with manufacturing, quality and regulatory management.

Bell’s Earlier Career Across Healthcare Companies

Before joining Alcon in 2016, Bell held senior leadership positions at Hospira and Allergan. These roles expanded his experience across the pharmaceutical and medical technology sectors before he moved into leadership at Alcon.

He began his professional career with GlaxoSmithKline, where he developed an early foundation in the healthcare industry.

His experience across these organizations has provided exposure to different business models, product categories and operational environments. The combination of pharmaceutical and medical device experience is particularly relevant to healthcare companies operating in highly regulated markets, where product quality, manufacturing reliability and regulatory compliance are essential.

Bell holds a Bachelor of Arts degree with honors in Economics from the University of York in the United Kingdom.

At Align, his background in global commercial operations, product innovation and manufacturing leadership is expected to provide additional insight into the company’s business activities. His experience at Alcon, particularly across surgical, vision care and digital health products, also offers a perspective from another medical technology market in which innovation and digital capabilities play important roles.

Align’s Business Focuses on Digital Orthodontics and Restorative Dentistry

The Board appointments come as Align continues to develop its portfolio of technologies for dental professionals and patients.

The company’s Invisalign® System uses clear aligner technology to support orthodontic treatment. Its iTero™ intraoral scanners enable digital capture of dental information, while its exocad™ CAD/CAM software supports digital design and manufacturing workflows for restorative dentistry.

Together, these products form an integrated portfolio that serves different stages of digital dental care. Clear aligner systems support orthodontic treatment planning and delivery, intraoral scanning provides digital representations of patients’ teeth and oral structures, and CAD/CAM software supports the design of dental restorations.

As dental practices increasingly adopt digital tools, companies in the sector must continue to consider technology development, product quality, clinical workflows and the needs of dental professionals. Align’s Board will play an important governance and oversight role as the company evaluates its strategic priorities and manages its global business.

The addition of Clancy and Bell brings experience from other healthcare sectors that face similar requirements involving innovation, regulatory oversight, financial planning and international operations.

Clancy’s background in financial management and corporate strategy may support Board discussions around capital allocation, financial performance and long-term business planning. Bell’s experience in medical technology operations may provide perspectives on product development, manufacturing, quality systems and international commercial execution.

Board Composition and 2027 Shareholder Meeting

Align Technology confirmed that Clancy and Bell will be included in the company’s slate of director nominees in the proxy statement for Align’s 2027 Annual Meeting of Shareholders.

Following Clancy’s appointment and Bell’s appointment on December 10, 2026, the Board will consist of 13 directors. The Board composition is scheduled to change again on December 31, 2026, when the previously announced retirement of C. Raymond Larkin, Jr. will take effect.

Following Larkin’s retirement, the number of directors serving on Align’s Board will decrease from 13 to 12.

The planned changes represent an update to the company’s Board leadership structure as Align prepares for its 2027 shareholder meeting. The inclusion of Clancy and Bell in the director nominee slate will provide shareholders with the opportunity to consider their appointments as part of the company’s annual governance process.

Strengthening Governance and Long-Term Strategic Oversight

The appointments of Paul J. Clancy and Ian Bell add two executives with substantial experience in global healthcare businesses to Align Technology’s Board of Directors.

Clancy brings more than three decades of financial, strategic and operational leadership, including senior CFO positions at Biogen and Alexion, as well as board experience at several life sciences companies. Bell contributes international medical technology leadership, with responsibilities spanning commercial operations, manufacturing, quality, regulatory affairs and product innovation at Alcon.

Their combined backgrounds provide expertise across financial governance, corporate strategy, product development and global healthcare operations. These capabilities are expected to complement the existing Board as Align continues to advance its digital orthodontics and restorative dentistry businesses.

With Clancy’s appointment effective immediately and Bell scheduled to join on December 10, 2026, Align is adding leadership experience from across the broader healthcare industry. The company will include both executives in its director nominee slate for the 2027 Annual Meeting of Shareholders, while the planned retirement of C. Raymond Larkin, Jr. at the end of December will bring the Board’s membership to 12 directors.

The changes reflect Align’s continued focus on Board experience and oversight as it pursues its long-term strategy in the global dental technology market.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 307 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide.

Over the past 29 years, Align has helped doctors treat approximately 24.2 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. 

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter